Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

This study is testing a combination of two cancer drugs — tivozanib and nivolumab — in people with a rare type of kidney cancer that is not the most common kind (non-clear cell renal cell carcinoma). **You may be eligible if...** - You have been diagnosed with metastatic non-clear cell kidney cancer (papillary, chromophobe, oncocytic, unclassified, or not otherwise specified) - You are 18 years or older - You have measurable tumors on scans - You have had no more than one prior treatment for this cancer - Your general health is reasonably good (able to care for yourself) **You may NOT be eligible if...** - You have medullary carcinoma of the kidney or collecting duct tumors - You have autoimmune disease or are on immune-suppressing medications - You have active brain metastases requiring treatment - You are pregnant or breastfeeding - Your organ function (liver, kidney, heart) is significantly impaired Talk to your doctor to see if this trial is right for you.